CTLA4 and cancer: Preclinical murine models have demonstrated that CTLA-4 blockade promotes cancer regression by increasing the frequency of effector T cells within the TME and selectively depleting intra-tumoral regulatory T cells via an Fc-dependent mechanism (Sharma et al. 1233).